Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic
treatment of psoriatic arthritis (PsA), as a collaboration between the American College …

Objective To update evidence‐based recommendations for the treatment of patients with
ankylosing spondylitis ( AS ) and nonradiographic axial spondyloarthritis (SpA). Methods We …

Ankylosing spondylitis is the prototype of immune-mediated inflammatory rheumatic diseases
grouped under the term spondyloarthritis (SpA). An early diagnosis has now become …

Background Secukinumab is an anti–interleukin-17A monoclonal antibody that has been
shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two …

Background Therapeutic targets have been defined for diseases like diabetes, hypertension
or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just …

Objective To provide evidence‐based recommendations for the treatment of patients with
ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods A core …

Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …

Background We assessed the efficacy and safety of brodalumab, a human monoclonal
antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, …

Background Secukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody
that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the …

Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐controlled
studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients …